Opinion
Robert D. Clark, Ulf Norinder
Published Online: May 20 2011
DOI: 10.1002/wcms.69
Abstract
Chemists working with small molecules are under enormous pressure to be able to reliably predict how biological systems in
particular and the environment in general will respond to the deployment of the corresponding compounds as medicines, cosmetics,
or in other manufactured goods. To be specific and robust, any such prediction must be based on an implicit or explicit mathematical
model of how chemical structure relates to biological activity—i.e., on some postulated quantitative structure–activity relationship
(QSAR). Such models are necessarily limited in how broadly they can be applied. Their applicability domain depends on the
structural diversity of the data set used, but also on the descriptors used to characterize how that structural variation
relates to the activity in question. In principle, descriptors based on the molecular interaction fields produced by atoms
distributed in three‐dimensional (3D) space should be the most general of all, but finding suitable conformations and alignment
is a challenge. One way to obtain these is by taking the structure of the macromolecular target into account as well, as is
done in scoring ligand/receptor complexes for virtual screening. Unfortunately, the available docking tools are generally
not up to the task. Here, we share some personal observations and opinions on two possible ways to address this shortcoming:
implicitly, by iterative rescoring of docked poses obtained using derived 3D QSARs; and explicitly, by evaluating ligand interaction
fields with respect to target atoms rather than against generalized probe atoms. © 2011 John Wiley & Sons, Ltd.
References 1 Netzeva TI,Worth AP,Aldenberg T,Benigni R,Cronin MTD,Gramatica P,Jaworska JS,Kahn S,Klopman G,Marchant CA, et al. Current status of methods for defining the applicability domain of (quantitative) structureactivity relationships. The report and recommendations of ECVAM workshop 521 ATLA 2005 33:155-173 2 Tetko IV,Bruneau P,Mewes H-W,Rohrer DC,Poda GI. Can we estimate the accuracy of ADMETox predictions? Drug Disco Today 2006 11:700-707 3 Warren GL,Andrews CW,Capelli A-M,Clarke B,LaLonde J,Lambert MH,Lindvall M,Nevins N,Semus SF,Senger S, et al. A critical assessment of docking programs and scoring functions J Med Chem 2006 49:5912-5931 4 Enyedy IJ,Egan WJ. Can we use docking and scoring for hit-to-lead optimization? J Comput Aided Mol Des 2008 22:161-168 5 Cramer RD III,Patterson DE,Bunce JD. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins J Am Chem Soc 1988 110:5959-5967 6 Klebe G,Abraham U,Mietzner T. Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity J Med Chem 1994 37:4130-4146 7 Watson KA,Mitchell EP,Johnson LN,Cruciani G,Son JC,Bichard CJF,Fleet GWJ,Oikonomakos NG,Kontou M,Zographos SE. Glucose analogue inhibitors of glycogen phosphorylase: from crystallographic analysis to drug prediction using GRID force field and GOLPE variable selection Acta Cryst 1995 D51:458-472 8 Cho SJ,Tropsha A. Cross-validated R2-guided region selection for comparative molecular field analysis: a simple method to achieve consistent results J Med Chem 1995 1060-1066 9 Norinder U. Single and domain mode variable selection in 3D QSAR applications J Chemometrics 1996 10:95-105 10 Wang R,Gao Y,Liu L,Lai L. All-orientation search and all-placement search in comparative molecular field analysis J Mol Model 1998 4:276-283 11 Prasanna S,Daga PR,Xie A,Doerksen RJ. Glycogen synthase kinase-3 inhibition by 3-anilino-4-phenylmaleimides: insights from 3D-QSAR and docking J Comput Aided Mol Des 2009 23:113-127 12 Murugesan V,Prabhakar YS,Katti SB. CoMFA and CoMSIA studies on thiazolidin-4-one as anti-HIV-1 agents J Mol Graph Model 2009 27:735-743 13 Patel PD,Patel MR,Kaushik-Basu N,Talele TT. 3D QSAR and molecular docking studies of benzimidazole derivatives as hepatitis C virus NS58 polymerase inhibitors J Chem Inf Model 2008 48:42-55 14 Sheng C,Zhang W,Ji H,Zhang M,Song Y,Xu H,Zhu J,Miao Z,Jiang Q,Yao J, et al. Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking J Med Chem 2006 49:2512-2525 15 Guido RVC,Oliva G,Montanari CA,Andricopulo AD. Structural basis for selective inhibition of trypanosomatid glyceraldehyde-3-phosphate dehydrogenase: molecular docking and 3D QSAR studies J Chem Inf Model 2008 48:918-929 16 Cozzini P,Kellogg GE,Spyrakis F,Abraham DJ,Costantino G,Emerson A,Fanelli F,Gohlke H,Kuhn LA,Morris GM. Target flexibility: an emerging consideration in drug discovery and design J Med Chem 2008 51:6237-6255 17 Clark RD. A ligand`s-eye view of protein binding J Comput Aided Mol Des 2008 22:507-521 18 Jain AN. Surflex-Dock 2.1: robust performance from ligand energetic modeling, ring flexibility, and knowledge-based search J Comput Aided Mol Des 2007 21:281-306 19 Wolohan P,Reichert DE. CoMFA and docking study of novel estrogen receptor subtype selective ligands J Comput Aided Mol Des 2003 17:313-328 20 Huang N,Shoichet BK,Irwin JJ. Benchmarking sets for molecular docking J Med Chem 2006 49:6789-6801 21 Ortiz AR,Pisabarro MT,Gago F,Wade RC. Prediction of drug binding affinities by comparative binding energy analysis J Med Chem 1995 38:2681-2691 22 Enyedy IJ,Egan WJ. Can we use docking and scoring for hit-to-lead optimization? J Comput Aided Mol Des 2008 22:161-168 23 Lushington GH,Guo J-X,Wang JL. Whither combine? New opportunities for receptor-based QSAR Curr Med Chem 2007 14:1863-1877